Gene: DHRS12
Official Full Name: dehydrogenase/reductase 12provided by HGNC
Gene Summary: This gene encodes a member of the short-chain dehydrogenases/reductases (SDR) family, which has over 46,000 members. Members in this family are enzymes that metabolize many different compounds, such as steroid hormones, prostaglandins, retinoids, lipids and xenobiotics. Alternative splicing results in multiple transcript variants and protein isoforms. [provided by RefSeq, Jul 2012]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO18299 | DHRS12 Knockout cell line (HeLa) | Human | DHRS12 | 1:3~1:6 | Negative | Online Inquiry |
KO18300 | DHRS12 Knockout cell line (HCT 116) | Human | DHRS12 | 1:2~1:4 | Negative | Online Inquiry |
KO18301 | DHRS12 Knockout cell line (HEK293) | Human | DHRS12 | 1:3~1:6 | Negative | Online Inquiry |
KO18302 | DHRS12 Knockout cell line (A549) | Human | DHRS12 | 1:3~1:4 | Negative | Online Inquiry |
DHRS12 Gene Knockout Cell Lines represent a cutting-edge tool for studying the biological functions of the DHRS12 gene, known for its role in various metabolic pathways and physiological processes. These cell lines are engineered to specifically disrupt the DHRS12 gene, allowing researchers to investigate the gene's function through loss-of-function studies. By knocking out DHRS12, scientists can elucidate its contributions to important cellular mechanisms, including steroid metabolism, redox balance, and lipid biosynthesis.
The primary mechanism behind these knockout cell lines involves CRISPR-Cas9 technology, which enables precise editing of the genome to create a stable, homozygous knockout. This ensures that all cells in the line lack functional DHRS12, providing a consistent model for experimentation. Researchers can utilize these cell lines in various experimental designs, including drug screening, metabolic assessments, and signaling pathway analyses, facilitating a deeper understanding of disease states related to DHRS12 dysregulation.
Scientifically, the DHRS12 Gene Knockout Cell Lines are valuable for applications in both research and clinical settings. They support investigations into metabolic disorders, cancers, and age-related diseases, where DHRS12 may play a significant role. This product is particularly advantageous because it provides a reliable and reproducible model that can lead to new therapeutic targets and insights, overcoming the limitations of primary cell cultures or transient knockdown methods that often lack stability and consistency.
What sets our DHRS12 Gene Knockout Cell Lines apart from alternatives is the rigorous validation process we employ, ensuring the knockout efficiency and specificity of our cell lines. Furthermore, they come with comprehensive user support and documentation to facilitate seamless integration into ongoing research workflows.
By providing researchers and clinicians with high-quality, ready-to-use knockout models, we enable them to advance their studies and discover new pathways to therapeutic intervention. Our expertise in genetic engineering and cell biology ensures that you are equipped with the most innovative tools, driving forward the frontiers of scientific discovery.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.